Loading
Loading
Research Overview
Nonapeptide secreted by thymic epithelial cells; requires zinc for biological activity; promotes T-lymphocyte differentiation and modulates cytokine production including IL-2; levels decline significantly with age, supporting interest in replacement research.
Thymulin is a naturally occurring peptide produced by the thymus gland and has been widely studied in preclinical research for its role in immune system signaling and regulation. Structurally, it is a nonapeptide that becomes biologically active when associated with zinc, forming a complex that has been observed to participate in immune cell differentiation and function. Because of its endogenous origin, Thymulin is often explored as part of broader investigations into thymic activity and immune system development under controlled experimental conditions.
Across laboratory and animal-based models, Thymulin has been examined for its potential involvement in T-cell maturation, immune communication, and regulatory balance within the immune system. Research has explored how it may influence cytokine production, cellular signaling pathways, and interactions between immune and neuroendocrine systems. These studies often focus on how Thymulin contributes to maintaining immune homeostasis, particularly in relation to thymic function and age-associated changes in immune responsiveness.
Beyond its immunological relevance, Thymulin has also been investigated for potential connections to neuroendocrine regulation in experimental settings. Some findings suggest it may interact with signaling pathways linked to inflammation, hormonal balance, and stress-related responses. This has led to interest in how thymic peptides like Thymulin may play a role in broader physiological coordination between the immune and endocrine systems.
To support consistent research outcomes, Thymulin has been synthesized and stabilized for laboratory use, often in its zinc-bound form to preserve biological activity. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, thymulin peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Thymulin Peptide research is most relevant to protocols examining:
Thymic function and T-lymphocyte differentiation research
Age-related immune senescence investigations
Zinc-dependent immune signalling studies
IL-2 cytokine modulation and T-cell activation research
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Minutes). Review data, confirm baseline recovery before any repeat protocol.
Nonapeptide secreted by thymic epithelial cells; requires zinc for biological activity; promotes T-lymphocyte differentiation and modulates cytokine production including IL-2; levels decline significantly with age, supporting interest in replacement research.
| Parameter | Value |
|---|---|
| Dose range | 0.2–1 mg/day (cycled) |
| Schedule | Daily (cycled) |
| Route | Subcutaneous |
| Half-life | ~Minutes |
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.